Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2025)

BioNexus Gene Lab's Cash & Equivalents history spans 8 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 56.74% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, down 56.74%, while the annual FY2024 figure was $1.6 million, 64.95% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $1.2 million at BioNexus Gene Lab, up from $814179.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $5.8 million in Q1 2024 and bottomed at $814179.0 in Q2 2025.
  • The 5-year median for Cash & Equivalents is $1.8 million (2022), against an average of $2.3 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 221.75% in 2023 before it crashed 81.29% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $2.1 million in 2021, then fell by 0.24% to $2.1 million in 2022, then skyrocketed by 113.21% to $4.5 million in 2023, then crashed by 64.95% to $1.6 million in 2024, then fell by 27.18% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cash & Equivalents are $1.2 million (Q3 2025), $814179.0 (Q2 2025), and $1.1 million (Q1 2025).